Zavicefta

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
20-02-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
20-02-2024

Viambatanisho vya kazi:

avibactam sodium, ceftazidime pentahydrate

Inapatikana kutoka:

Pfizer Ireland Pharmaceuticals

ATC kanuni:

J01

INN (Jina la Kimataifa):

ceftazidime, avibactam

Kundi la matibabu:

Antibacterials for systemic use,

Eneo la matibabu:

Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections

Matibabu dalili:

Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Bidhaa muhtasari:

Revision: 15

Idhini hali ya:

Authorised

Idhini ya tarehe:

2016-06-23

Taarifa za kipeperushi

                                29
B. PACKAGE LEAFLET
30
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZAVICEFTA 2 G/0.5 G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
ceftazidime/avibactam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Zavicefta is and what it is used for
2.
What you need to know before you use Zavicefta
3.
How to use Zavicefta
4.
Possible side effects
5.
How to store Zavicefta
6.
Contents of the pack and other information
1.
WHAT ZAVICEFTA IS AND WHAT IT IS USED FOR
WHAT ZAVICEFTA IS
Zavicefta is an antibiotic medicine that contains two active
substances ceftazidime and avibactam.

Ceftazidime belongs to the group of antibiotics called
“cephalosporins”. It can kill many types
of bacteria.

Avibactam is a “beta-lactamase inhibitor” that helps ceftazidime
kill some bacteria that it cannot
kill on its own.
WHAT ZAVICEFTA IS USED FOR
Zavicefta is used in adults and paediatric patients aged 3 months and
over to treat:

infections of the stomach and gut (abdomen)

infections of the bladder or kidneys called “urinary tract
infections”

an infection of the lungs called “pneumonia”

infections caused by bacteria that other antibiotics may not be able
to kill
Zavicefta is used in adults to treat infection of the blood associated
with infections of the abdomen,
urinary tract, or pneumonia.
HOW ZAVICEFTA WORKS
Zavicefta works by killing certain types of bacteria, which can cause
serious infections.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE ZAVICEFTA
DO NOT USE ZAVICEFTA IF:

you are allergic to ceftazidime, avibactam or any of the other
ingredients of this medicine (listed
in section 6)

you are allergic to other cephalosporin antibiotics

                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains ceftazidime pentahydrate equivalent to 2 g
ceftazidime and avibactam sodium
equivalent to 0.5 g avibactam.
After reconstitution, 1 mL of solution contains 167.3 mg of
ceftazidime and 41.8 mg of avibactam (see
section 6.6).
Excipient with known effect:
Zavicefta contains approximately 146 mg sodium per vial.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion (powder for
concentrate).
A white to yellow powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Zavicefta is indicated in adults and paediatric patients aged 3 months
and older for the treatment of the
following infections (see sections 4.4 and 5.1):

Complicated intra-abdominal infection (cIAI)

Complicated urinary tract infection (cUTI), including pyelonephritis

Hospital-acquired pneumonia (HAP), including ventilator associated
pneumonia (VAP)
Treatment of adult patients with bacteraemia that occurs in
association with, or is suspected to be
associated with, any of the infections listed above.
Zavicefta is also indicated for the treatment of infections due to
aerobic Gram-negative organisms in
adults and paediatric patients aged 3 months and older with limited
treatment options (see sections 4.2,
4.4 and 5.1).
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
It is recommended that Zavicefta should be used to treat infections
due to aerobic Gram-negative
organisms in adults and paediatric patients aged 3 months and older
with limited treatment options
only after consultation with a physician with appropriate experience
in the management of infectious
diseases (see section 4.4).
3
Posology
_Dosage in adults with creatinine clearance (CrCL) > 50 mL/min_
Table 1 shows the reco
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kireno 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 20-11-2020
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 20-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 20-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 20-02-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 20-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 20-11-2020

Tazama historia ya hati